Passage Bio Stock Total Debt
| PASG Stock | USD 0.51 0.03 5.56% |
Passage Bio fundamentals help investors to digest information that contributes to Passage Bio's financial success or failures. It also enables traders to predict the movement of Passage Stock. The fundamental analysis module provides a way to measure Passage Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Passage Bio stock.
The current Total Debt To Capitalization is estimated to decrease to 0.02. Passage | Total Debt |
Passage Bio Company Total Debt Analysis
Passage Bio's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Passage Bio Total Debt | 26.29 M |
Most of Passage Bio's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Passage Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Passage Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Passage Bio is extremely important. It helps to project a fair market value of Passage Stock properly, considering its historical fundamentals such as Total Debt. Since Passage Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Passage Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Passage Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Passage Total Debt Historical Pattern
Today, most investors in Passage Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Passage Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Passage Bio total debt as a starting point in their analysis.
Passage Bio Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Passage Net Debt
Net Debt |
|
Based on the latest financial disclosure, Passage Bio has a Total Debt of 26.29 M. This is 99.04% lower than that of the Biotechnology sector and 91.9% lower than that of the Health Care industry. The total debt for all United States stocks is 99.51% higher than that of the company.
Passage Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in total debt category among its peers.
Passage Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Passage Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Passage Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Passage Bio's value.| Shares | Fiduciary Trust Co | 2024-09-30 | 215 K | Citadel Advisors Llc | 2024-06-30 | 158.3 K | Rbf Llc | 2024-06-30 | 142.8 K | State Street Corp | 2024-06-30 | 123.9 K | Two Sigma Investments Llc | 2024-06-30 | 103.9 K | Marquette Asset Management Inc. | 2024-06-30 | 85.5 K | Northern Trust Corp | 2024-09-30 | 40.3 K | Goldman Sachs Group Inc | 2024-06-30 | 27.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 26.9 K | Orbimed Advisors, Llc | 2024-06-30 | 10.1 M | Vestal Point Capital Lp | 2024-06-30 | 6.1 M |
Passage Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (25.9 M) | ||||
| Shares Outstanding | 61.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 59.68 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Book | 0.46 X | ||||
| EBITDA | (98.34 M) | ||||
| Net Income | (102.06 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 26.29 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (78.26 M) | ||||
| Short Ratio | 6.61 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Target Price | 7.67 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 33.11 M | ||||
| Total Asset | 150.54 M | ||||
| Retained Earnings | (594.47 M) | ||||
| Working Capital | 101.62 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 150.54 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.